NEW YORK, April 04, 2026 (GLOBE NEWSWIRE) —
WHY: Rosen Legislation Agency, a world investor rights regulation agency, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, each dates inclusive (the “Class Period”), of the essential Could 26, 2026 lead plaintiff deadline within the securities class motion first filed by the Agency.
SO WHAT: Should you bought ImmunityBio securities throughout the Class Interval you might be entitled to compensation with out cost of any out of pocket charges or prices by a contingency payment association.
WHY ROSEN LAW: We encourage buyers to pick certified counsel with a monitor document of success in management roles. Usually, corporations issuing notices wouldn’t have comparable expertise, assets, or any significant peer recognition. Many of those corporations don’t truly deal with securities class actions, however are merely middlemen that refer shoppers or companion with regulation corporations that really litigate the instances. Be smart in deciding on counsel. The Rosen Legislation Agency represents buyers all through the globe, concentrating its observe in securities class actions and shareholder by-product litigation. Rosen Legislation Agency has achieved, at the moment, the biggest ever securities class motion settlement in opposition to a Chinese language Firm. Rosen Legislation Agency was Ranked No. 1 by ISS Securities Class Motion Companies for variety of securities class motion settlements in 2017. The agency has been ranked within the high 4 every year since 2013 and has recovered tons of of hundreds of thousands of {dollars} for buyers. In 2019 alone the agency secured over $438 million for buyers. In 2020, founding companion Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Most of the agency’s attorneys have been acknowledged by Lawdragon and Tremendous Legal professionals.
DETAILS OF THE CASE: In line with the lawsuit, defendants all through the Class Interval made false and/or deceptive statements and/or didn’t disclose that: (1) defendant Patrick Quickly-Shiong materially overstated Anktiva’s capabilities; and (2) because of this, defendants’ statements about ImmunityBio’s enterprise, operations, and prospects had been materially false and deceptive and/or lacked an affordable foundation in any respect related occasions. When the true particulars entered the market, the lawsuit claims that buyers suffered damages.
More Read
No Class Has Been Licensed. Till a category is licensed, you aren’t represented by counsel except you keep one. It’s possible you’ll choose counsel of your selection. You might also stay an absent class member and do nothing at this level. An investor’s capability to share in any potential future restoration will not be dependent upon serving as lead plaintiff.
Lawyer Promoting. Prior outcomes don’t assure the same consequence.
——————————-
More Read
Contact Data:
